INTRODUCTION: Treatment-related neuroendocrine prostate cancer, a rare and aggressive malignancy that emerges during androgen deprivation therapy characterized by low serum prostate-specific antigen concentrations, is challenging to monitor because it is associated with predominantly visceral and lytic bone metastases. CASE PRESENTATION: We describe the case of a 69-year-old man with treatment-related neuroendocrine prostate cancer in whom the treatment response could be monitored using whole-body diffusion-weighted magnetic resonance imaging in addition to serum concentrations of neuroendocrine markers. The patient responded well to platinum-based chemotherapy and achieved a complete response, as evidenced by these diagnostic modalities. CONCLUSION: Our case suggests that whole-body diffusion-weighted magnetic resonance imaging is useful in disease management for treatment-related neuroendocrine prostate cancer as well as the potential evaluation of mixed responses and treatment resistance.
INTRODUCTION: Treatment-related neuroendocrine prostate cancer, a rare and aggressive malignancy that emerges during androgen deprivation therapy characterized by low serum prostate-specific antigen concentrations, is challenging to monitor because it is associated with predominantly visceral and lytic bone metastases. CASE PRESENTATION: We describe the case of a 69-year-old man with treatment-related neuroendocrine prostate cancer in whom the treatment response could be monitored using whole-body diffusion-weighted magnetic resonance imaging in addition to serum concentrations of neuroendocrine markers. The patient responded well to platinum-based chemotherapy and achieved a complete response, as evidenced by these diagnostic modalities. CONCLUSION: Our case suggests that whole-body diffusion-weighted magnetic resonance imaging is useful in disease management for treatment-related neuroendocrine prostate cancer as well as the potential evaluation of mixed responses and treatment resistance.
Authors: Himisha Beltran; Scott T Tagawa; Kyung Park; Theresa MacDonald; Matthew I Milowsky; Juan Miguel Mosquera; Mark A Rubin; David M Nanus Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: Daniel E Spratt; Somali Gavane; Lisa Tarlinton; Shoaib B Fareedy; Michael G Doran; Michael J Zelefsky; Joseph R Osborne Journal: Prostate Date: 2014-06-09 Impact factor: 4.104
Authors: Anwar R Padhani; Frederic E Lecouvet; Nina Tunariu; Dow-Mu Koh; Frederik De Keyzer; David J Collins; Evis Sala; Stefano Fanti; H Alberto Vargas; Giuseppe Petralia; Heinz Peter Schlemmer; Bertrand Tombal; Johann de Bono Journal: Eur Urol Focus Date: 2016-07-15